Trial · NCT07882628
Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
NCT07882628, Not yet recruiting, Beijing Chao Yang Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer. Trials, record NCT07882628. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882628
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer
- NCT number
- NCT07882628
- Status
- Not yet recruiting
- Enrollment
- 1,050 participants, estimated
- Lead sponsor
- Beijing Chao Yang Hospital
- Conditions
- Pulmonary Nodules, Early Detection of Cancer, Lung Neoplasms
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sub-study 1:Area under the receiver operating characteristic curve (AUC) of the multi-modal diagnostic model | Up to 12 months after participant enrollment, after final pathological diagnosis of pulmonary nodules is obtained | To assess the diagnostic performance of the multi-modal model combining CT imaging, tumor autoantibodies and multi-omics data for differentiating early-stage lung cancer from benign pulmonary nodules. Pathological results serve as the gold standard. The primary endpoint is the AUC of the model. |
| Primary | Sub-study2:Area under the receiver operating characteristic curve (AUC) of three-dimensional interference microscopy | Up to 12 months after participant enrollment, after final pathological diagnosis is obtained | To evaluate the diagnostic performance of three-dimensional interference microscopy in differentiating malignant and benign pulmonary nodules based on bronchoscopic biopsy samples. Final pathological diagnosis is used as the gold standard. The primary outcome is the AUC of the microscopic imaging method. |
| Secondary | Sub-study1&2:Overall Survival (OS) | 24 months after participant enrollment | Overall survival is defined as the time from the date of surgery to death from any cause. All-cause mortality will be documented during the follow-up period. |
| Secondary | Sub-study1&2:Tumor recurrence or progression | 24 months after participant enrollment | Tumor recurrence or disease progression is determined according to the RECIST 1.1 criteria or comprehensive multidisciplinary judgment based on serial imaging and clinical data. Events include local recurrence, new lesion emergence, or significant enlargement of existing lesions. |
| Secondary | Sub-study1&2:Tumor metastasis | 24 months after participant enrollment | Tumor metastasis is defined as tumor spread to regional lymph nodes or distant organs during follow-up, confirmed by imaging evidence and comprehensive clinical evaluation. All metastatic events will be recorded. |
| Other | Sub-study1:Levels of lung cancer-associated autoantibodies | Up to 24 months after participant enrollment | Exploratory detection of lung cancer-associated autoantibodies in serum samples collected from participants in the surgical sub-cohort. The distribution of autoantibody levels will be compared between malignant and benign pulmonary nodule groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882628
GET https://conductscience.org/api/trials/v1/NCT07882628/registered